UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 23, 2003
BIOJECT MEDICAL TECHNOLOGIES INC. | ||
(Exact name of registrant as specified in its charter) | ||
|
|
|
Oregon |
| 93-1099680 |
(State or other jurisdiction of incorporation |
| (I.R.S. Employer Identification No.) |
|
|
|
211 Somerville Road, Route 202 North, |
| 07921 |
(Address of principal executive offices) |
| (Zip Code) |
|
|
|
Registrant’s telephone number, including area code: (908) 470-2800 | ||
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
Item | Description |
|
|
Financial Statements, Pro Forma Financial Information and Exhibits | |
|
|
Regulation FD Disclosure (Information provided pursuant to Item 12). | |
|
|
1
Item 7. Financial Statements and Exhibits
(c) Exhibits
This list is intended to constitute the exhibit index:
99.1 Press release dated April 23, 2003 regarding Bioject’s first quarter 2003 revenue and earnings.
Item 9. Regulation FD Disclosure (Information provided pursuant to Item 12)
On April 23, 2003 Bioject announced a net loss of $2.2 million, or $(0.21) per share, on revenue of $1.1 million for its first quarter of 2003 ended March 31, 2003.
A copy of the April 23, 2003 press release is included as exhibit 99.1 hereto. This exhibit is not filed, but is furnished pursuant to Item 12. (a) of Form 8-K.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 23, 2003 | BIOJECT MEDICAL TECHNOLOGIES INC. | |
| (Registrant) | |
|
| |
|
| |
|
| |
| /s/ JAMES O’SHEA |
|
| James O’Shea | |
| Chairman of the Board, Chief Executive Officer | |
|
| |
|
| |
|
| |
| /s/ JOHN GANDOLFO |
|
| John Gandolfo | |
| Chief Financial Officer and Vice President of Finance | |
3
